Issue 128 • March 2023
In association with
‘Right shoring’ API production in Europe
Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
DCTs in 2023: New year’s resolutions for decentralised clinical trials
Inside the hunt for an Alzheimer’s disease vaccine
Are we entering the era of biologics for COPD?
CMO Moves: Regulatory catalysts for drug manufacturing-February
4D Molecular’s Fabry gene therapy program on FDA clinical hold
Price is key for market adoption of Amgen’s Amjevita
Wegovy: the latest weight loss fad
PROTAC development gains momentum, but clinical performance is poor
FDA head Califf calls on tighter accelerated approvals and lower drug prices